Milurit (Allopurinol)

Allopurinol, the active ingredient in Milurit, is a xanthine oxidase inhibitor presented as an oral tablet for systemic use. It reduces uric acid production and is employed in the management of gout, chronic hyperuricemia, and prevention of tumor lysis syndrome in at‑risk patients, primarily in adult patients.

GNH USA supplies Milurit as a licensed, GDP‑compliant international pharmaceutical product to hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including regulatory compliance and timely delivery.

Allopurinol acts on purine metabolism to lower uric acid levels, making it useful in several clinical situations.

- Gout: reduces serum uric acid to prevent acute attacks and chronic joint damage. - Hyperuricemia: maintains target uric acid concentrations to avoid crystal deposition. - Tumor lysis syndrome prophylaxis: lowers uric acid surge during cancer chemotherapy. - Uric acid nephrolithiasis: helps prevent stone formation.

Allopurinol may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Rash or mild skin irritation. - Nausea or upset stomach. - Diarrhea. - Elevated liver enzymes.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Drug hypersensitivity syndrome with fever and organ involvement. - Agranulocytosis or severe bone‑marrow suppression. - Acute hepatitis. - Severe renal impairment.

Use Milurit with caution in specific clinical contexts and monitor relevant parameters.

- Renal impairment: dose may need adjustment and renal function should be monitored. - Hepatic disease: use cautiously and monitor liver enzymes regularly. - Allergy history: avoid if the patient has previously experienced hypersensitivity to allopurinol. - Concomitant azathioprine or mercaptopurine: increased risk of myelosuppression; monitor blood counts. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Allopurinol can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Azathioprine or mercaptopurine: combined use can markedly increase myelosuppression. - Warfarin: allopurinol may potentiate anticoagulant effect; INR should be closely monitored.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may reduce allopurinol clearance, requiring uric‑acid monitoring. - ACE inhibitors: occasional rise in serum creatinine; renal function should be checked. - High‑dose vitamin C: can affect uric‑acid levels; observe for therapeutic response.